![Nicolas Poirier](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Nicolas Poirier
Keine laufenden Positionen mehr
Vermögen: 6 Mio $ am 31.05.2026
Profil
Nicolas Poirier worked as a Project Manager at Effimune SA. From 2016 to 2026, Dr. Poirier worked at OSE Immunotherapeutics SA, serving as Chief Scientific Officer from 2025 to 2026.
Dr. Poirier completed undergraduate studies at Centre d'Etudes Supérieures de Techniques Industrielles and graduate degrees at the University of Nantes and Louis Pasteur University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 12.09.2025 | 1 131 603 ( 4,99 % ) | 6 Mio $ | 31.05.2026 |
Ehemalige bekannte Positionen von Nicolas Poirier
| Unternehmen | Position | Ende |
|---|---|---|
| OSE IMMUNOTHERAPEUTICS | Vorstandsvorsitzender | 02.10.2025 |
Effimune SA
 Effimune SA BiotechnologyHealth Technology Engages in the research and development of drugs for transplantation and immune-mediated diseases | Corporate Officer/Principal | - |
Ausbildung von Nicolas Poirier
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
16
Beziehungen ersten Grades
5
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 5 |
|---|---|
University of Nantes
 University of Nantes Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Effimune SA
Effimune SA BiotechnologyHealth Technology Engages in the research and development of drugs for transplantation and immune-mediated diseases | Health Technology |
Centre d'Etudes Supérieures de Techniques Industrielles
 Centre d'Etudes Supérieures de Techniques Industrielles Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
OSE Immunotherapeutics SA
 OSE Immunotherapeutics SA Pharmaceuticals: MajorHealth Technology Develops immunotherapy products for late-stage cancers | Health Technology |
Louis Pasteur University
 Louis Pasteur University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
